Drug makers asked US regulators Thursday to authorize their coronavirus vaccine for younger children. Pfizer and BioNTech want the Food and Drug Administration to approve emergency use for those aged 5 to 11.
The Pfizer/BioNTech vaccine is already approved for emergency use for those aged 12 to 15. Company officials submitted data from clinical trials that suggest the shots provoke a strong immune response in younger children too.
Participants received about a third of the dose given to adults. They were given a second dose after three weeks. The trials showed the children produced antibodies at levels similar to those produced by teenagers and young adults.
Young people rarely become severely ill from the virus. But doctors say, last month, children accounted for one in four infections nationwide. The Delta variant has sent thousands to hospital.
An FDA advisory committee is scheduled to meet October 26 to review the data from the trials.